Group 1 - The CRO sector is experiencing a collective rebound, with notable stock price increases for companies such as Tigermed (up 9.19% to HKD 39.92), WuXi AppTec (up 4.43% to HKD 106), and others [1] - Citing a recovery in capital market financing activities and an expansion in the overseas trading scale of innovative drugs, the outlook for CXO companies' performance in the second half of the year is optimistic [1] - Morgan Stanley notes that since mid-September, healthcare stocks have been under pressure as investors take profits, but the fundamentals for WuXi's companies remain strong, making their valuations more attractive [1] Group 2 - WuXi AppTec is highlighted as a top pick due to its raised earnings guidance and significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The projected compound annual growth rates for WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary from 2024 to 2027 are 24%, 23%, and 37% respectively [1]